Abstract
S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.
| Original language | English |
|---|---|
| Pages (from-to) | 60-64 |
| Number of pages | 5 |
| Journal | Lung Cancer |
| Volume | 71 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2011 |
Fingerprint
Keywords
- Elderly
- Non-small cell lung cancer
- Radiation
- S-1
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research
Cite this
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. / Takigawa, Nagio; Kiura, Katsuyuki; Hotta, Katsuyuki; Hosokawa, Shinobu; Nogami, Naoyuki; Aoe, Keisuke; Gemba, Kenichi; Fujiwara, Keiichi; Harita, Shingo; Takemoto, Mitsuhiro; Himei, Kengo; Shinkai, Tetsu; Fujiwara, Yoshirou; Takata, Saburo; Tabata, Masahiro; Kanazawa, Susumu; Tanimoto, Mitsune.
In: Lung Cancer, Vol. 71, No. 1, 01.2011, p. 60-64.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer
AU - Takigawa, Nagio
AU - Kiura, Katsuyuki
AU - Hotta, Katsuyuki
AU - Hosokawa, Shinobu
AU - Nogami, Naoyuki
AU - Aoe, Keisuke
AU - Gemba, Kenichi
AU - Fujiwara, Keiichi
AU - Harita, Shingo
AU - Takemoto, Mitsuhiro
AU - Himei, Kengo
AU - Shinkai, Tetsu
AU - Fujiwara, Yoshirou
AU - Takata, Saburo
AU - Tabata, Masahiro
AU - Kanazawa, Susumu
AU - Tanimoto, Mitsune
PY - 2011/1
Y1 - 2011/1
N2 - S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.
AB - S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.
KW - Elderly
KW - Non-small cell lung cancer
KW - Radiation
KW - S-1
UR - http://www.scopus.com/inward/record.url?scp=78650195909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650195909&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2010.04.012
DO - 10.1016/j.lungcan.2010.04.012
M3 - Article
VL - 71
SP - 60
EP - 64
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 1
ER -